Immune Checkpoint Inhibition for Hepatocellular Carcinoma, Cholangiocarcinoma, and Combined Hepatocellular-Cholangiocarcinoma.

IF 2.2 Q3 ONCOLOGY
World Journal of Oncology Pub Date : 2025-06-01 Epub Date: 2025-05-13 DOI:10.14740/wjon2571
Keiko Shichiri, Kaity H Tung, Kazuaki Takabe, David L Bartlett
{"title":"Immune Checkpoint Inhibition for Hepatocellular Carcinoma, Cholangiocarcinoma, and Combined Hepatocellular-Cholangiocarcinoma.","authors":"Keiko Shichiri, Kaity H Tung, Kazuaki Takabe, David L Bartlett","doi":"10.14740/wjon2571","DOIUrl":null,"url":null,"abstract":"<p><p>Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma that is composed of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Given its low incidence, there is no standardized treatment protocol or systemic regimens. With the development of immune checkpoint inhibitors (ICIs), one of the immunotherapies that modulate the immune system by restoring antitumor immune response, studies have shown promising results for the use of ICI as systemic therapy for advanced solid tumors, including liver cancers. Moreover, prospective clinical studies displayed favorable outcomes of the use of ICIs in HCC and biliary tract cancers. Here, we review the recent evidence in application and comparison of ICIs for HCC, CCA, and cHCC-CCA as well as the future direction of systemic therapy for cHCC-CCA.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 3","pages":"243-253"},"PeriodicalIF":2.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185123/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon2571","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma that is composed of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Given its low incidence, there is no standardized treatment protocol or systemic regimens. With the development of immune checkpoint inhibitors (ICIs), one of the immunotherapies that modulate the immune system by restoring antitumor immune response, studies have shown promising results for the use of ICI as systemic therapy for advanced solid tumors, including liver cancers. Moreover, prospective clinical studies displayed favorable outcomes of the use of ICIs in HCC and biliary tract cancers. Here, we review the recent evidence in application and comparison of ICIs for HCC, CCA, and cHCC-CCA as well as the future direction of systemic therapy for cHCC-CCA.

免疫检查点抑制肝细胞癌、胆管癌和肝细胞胆管合并癌。
合并肝细胞胆管癌(cHCC-CCA)是一种罕见的原发性肝癌,由肝细胞癌(HCC)和胆管癌(CCA)组成。由于发病率低,目前尚无标准化的治疗方案或系统治疗方案。随着免疫检查点抑制剂(ICI)的发展,ICI作为一种通过恢复抗肿瘤免疫反应来调节免疫系统的免疫疗法,研究显示ICI作为晚期实体肿瘤(包括肝癌)的全身治疗有希望的结果。此外,前瞻性临床研究显示,在HCC和胆道癌症中使用ICIs具有良好的效果。在此,我们回顾了近年来ICIs在HCC、CCA和cHCC-CCA中的应用和比较的证据,以及cHCC-CCA全身治疗的未来方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
15.40%
发文量
37
期刊介绍: World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信